LONDON, ONTARIO--(Marketwire - May 06, 2008) - Sernova Corp. (TSX VENTURE: SVA) -
Sernova Corp. today announced the successful conclusion of a meeting with the U.S. Food and Drug Administration (FDA) that established definitive requirements for the filing of an Investigational New Drug (IND) application, which is required to advance Sertolin into human Clinical Trials. Sertolin is the Corporation's proprietary technology for treating insulin-dependent diabetes. After review of Sernova's pre-clinical testing data in rodents to date, the FDA specified that the next stage will be a pivotal pre-clinical trial consisting of a single large animal trial with clear endpoints, leading to a Phase I/II human Clinical Trial. The pivotal pre-clinical trial is expected to take about 18 months to complete and will assess the long-term safety and durable activity of Sertolin.
